09 March 2022

GSK Stockmann contributed to the publication of the cross-border comparative report Securities Litigation by Lexology Getting the Deal Through

The new edition of the cross-border comparative report Securities Litigation has been published by Lexology Getting the Deal Through providing international expert analysis for corporate counsels, cross-border legal practitioners as well as company directors and officers.

The guide enables side-by-side comparison regarding the mechanisms and procedures surrounding securities litigation across the world’s markets, covering: types of securities claim; remedies and damages; plea requirements; early stage procedural mechanisms for defendants; collective proceedings; third-party litigation funding; litigation involving investment funds and structured finance; requirements for foreign residents and security holders; the handling of multiple securities claims in different jurisdictions; and available alternatives to litigation.

GSK Stockmann contributed to the publication of the cross-border comparative report: Andreas Heinzmann (Partner at GSK Stockmann in Luxembourg) and Dr. Manuel Fernandez (Local Partner at GSK Stockmann in Luxembourg) composed the chapter “Luxembourg“.

The publication is available for download as a PDF file. The whole guide can be accessed on the Lexology website.

Print


Press contact
Beate Dünschede
+352 271802-29
beate.duenschede@gsk-lux.com

Back

GSK Updates
  • 28.02.2024

    GSK Update: GSK Stockmann contributed to the publication of the International Comparative Legal Guide to Mergers and Acquisitions

    Read more
  • 12.02.2024

    GSK Update: ESG regulation – an outlook on developments for the year 2024

    Read more
  • 12.02.2024

    GSK Update: Green securitisations under the new Europe-an Green Bonds Regulation

    Read more
Contact person

Andreas Heinzmann, LL.M. eur.

Partner

+352 271802-30

andreas.heinzmann@gsk-lux.com

Dr. Manuel Fernandez

Partner

+352 271802-31

manuel.fernandez@gsk-lux.com

© GSK Stockmann 2024